Parkinson's disease: Evidence for environmental risk factors

Movement Disorders

Volumn 28, Issue 1, 2013, Pages 8-13

  Kieburtz, Karl ^a   Wunderle, Kathryn B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Environmental factors; Gene environmental interactions; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PESTICIDE; URATE;

CHRONIC INFLAMMATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXERCISE; GENOTYPE ENVIRONMENT INTERACTION; GROUPS BY AGE; HUMAN; NERVE DEGENERATION; OCCUPATION; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TRAUMATIC BRAIN INJURY; URIC ACID BLOOD LEVEL;

AGE FACTORS; BRAIN INJURIES; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; EXERCISE; GENE-ENVIRONMENT INTERACTION; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 84873443346     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25150     Document Type: Review

References (41)

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011;26S1:S1-S58.
2. Bronstein J, Carvey P, Chen H, et al. Collaborative on Health and the Environment and Parkinson's Action Network (CHE PAN) Conference Consensus Statement. Environ Health Perspect 2009;117:117-121.
3. Bower JH, Maraganore DM, McDonnell SK, Shanno K, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
4. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
5. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004;75:637-639.
6. Taylor KSM, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:905-912.
7. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ, 3rd. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-209.
8. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding PD: an exploratory case-control study. Mov Disord 2001;16:830-837.
9. Hernàn MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
10. Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodriquez C, Thun MJ. Coffee consumption, gender, and Parkinson's disease mortality in the Cancer Prevention Study II Cohort: the modifying effects of estrogen. AM J Epidemiol 2004;160:977-984.
11. Tanner CM, Ross GW, Jewell SA, et al. Occupation and risk of parkinsonism. A multicenter case-control study. Arch Neurol 2009;66:1106-1113.
12. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat and Parkinson's disease. Environ Health Perspect 2011;119:866-872.
13. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009;169:919-926.
14. Dick FD, De Palma G, Ahmadi A, et al.; on behalf of the Geoparkinson study group. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007;64:666-672.
15. Hancock DB, Martin ER, Mayhew GM, et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 2008;8:6.
16. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
17. Schwarzschild MA, Schwid SR, Marek K, et al.; and the Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-723.
18. Chen H, Zhang SM, Hernàn MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
19. Hernàn MA, Logroscino G, Rodriquez LAG. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurol 2006;66:1097-1099.
20. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurol 2007;69:1836-1842.
21. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurol 2011;76:863-869.
22. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Ann Neurol 2006;60:65-72.
23. Goldman SM, Kamel F, Ross GW, et al. Head Injury, alpha-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012;71:40-48.
24. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD. A case-control study. Neurol 2003;60:1610-1615.
25. Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease. Mov Disord 2008;23:69-74.
26. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012;71:776-784.
27. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
28. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurol 2009;72(S3):S12-S20.
29. Becker C, Jick SS, Meier CR. NSAID use and the risk of Parkinson disease: a population-based case control study. Eur J Neurol 2011;18:1336-1342.
30. Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM. Non-steroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007;28:193-196.
31. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Non-steroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963-967.
32. Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
33. Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T. Use of NSAIDS and risk of Parkinson's disease: nested case control study. BMJ 2011;342:d198.
34. Gagne JJ, Power MC. 2010. Anti-inflammatory drugs and risk of Parkinson disease: a metaanalysis. Neurol 2010;74:995-1002.
35. Gao X, Chen H, Shwarszchild MH, Ascherio A. Use of ibuprofen and risk of Parkinson Disease. Neurol 2011;76:863-869.
36. Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and non-steroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64:576-580.
37. Hernán MA, Logroscino G, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurol 2006;66:1097-1099.
38. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88-95.
39. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009;26:769-779.
40. Ton TG, Heckbert SR, Longstreth WT, Jr., et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964-969.
41. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Non-steroidal anti-inflammatory drugs may protect against Parkinson disease. Neurol 2007;69:1836-1842.